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Abstract
Transforming growth factor (TGF)-bs are plausible candidate tumor suppressors in the breast.
They also have oncogenic activities under certain circumstances, however. Genetically altered
mouse models provide powerful tools to analyze the complexities of TGF-b action in the
context of the whole animal. Overexpression of TGF-b can suppress tumorigenesis in the
mammary gland, raising the possibility that use of pharmacologic agents to enhance TGF-b
function locally might be an effective method for the chemoprevention of breast cancer.
Conversely, loss of TGF-b response increases spontaneous and induced tumorigenesis in the
mammary gland. This confirms that endogenous TGF-bs have tumor suppressor activity in the
mammary gland, and suggests that the loss of TGF-b receptors seen in some human breast
hyperplasias may play a causal role in tumor development.
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Introduction
The hypothesis that transforming growth factor (TGF)-bs
may act as a tumor suppressors in the mammary gland
has considerable intuitive appeal. TGF-bs are expressed
at all stages of mammary development except lactation
[1••], and they have potent growth inhibitory effects on
mammary epithelial cells in vitro and in vivo [2,3]. Further-
more, many breast cancer cell lines have absent or
decreased TGF-b responsiveness [4], and decreased
expression of the type II TGF-b receptor in early premalig-
nant breast lesions is correlated with increased probability
of subsequent invasive disease [5••]. TGF-bs also have
pro-oncogenic activities, however, and advanced human
breast tumors overexpress TGF-bs [6]. This suggests that
the role of TGF-bs in breast cancer is probably complex.
The potential oncogenic and tumor suppressor activities
of TGF-bs are summarized in Figure 1.
We propose that TGF-bs are ‘conditional tumor suppres-
sors’, with suppressor activity depending on a variety of
factors, including the TGF-b responsiveness of the
mammary epithelium, the stage in tumorigenesis, the
nature of cooperating oncogenic events, and the level of
expression of TGF-b ligand and receptor. It will be critical
to define the precise circumstances under which TGF-bs
act as tumor suppressors in the breast if we are to exploit
the TGF-b system for therapy and/or prevention of breast
cancer. Genetically engineered mouse models provide an
invaluable experimental tool for this purpose, because
TGF-b function can be manipulated in the context of thehttp://breast-cancer-research.com/content/2/2/100
intact organism, where complex tissue interactions and reg-
ulatory cues are maintained. Also, whereas analysis of clini-
cal samples can reveal provocative correlations between
altered gene expression and tumorigenesis, animal studies
allow causal mechanistic connections to be established.
Two different approaches: ‘gain-of-function’
and ‘loss-of-function’
To date, there are five mouse models that have been gen-
erated specifically to elucidate TGF-b function in the
mammary gland (Table 1), and two more that give some
insight into the process (TGF-b1
+/– and Smad3–/– mice).
Two conceptually different types of approach are used in
the generation of models such as these, and we briefly
consider the advantages and limitations of these before
dealing with the specific results.
In the first, ‘gain-of-function’ approach, a protein is trans-
genically overexpressed in a target organ. This approach
establishes what a protein can do in a given tissue
context. It is of particular value for molecules such as
TGF-b, with action that is so strongly context-dependent
that the roles in vivo cannot readily be predicted from in
vitro activities. The caveat, however, is that the transgenic
protein is usually expressed at high levels, frequently in a
cell type that might not normally express it in vivo, and it is
not subject to all of the normal regulatory processes. Thus,
the phenotype may not necessarily reflect the true role of
the endogenous protein. In the second, ‘loss-of-function’
approach, a gene is knocked out by homologous recombi-
nation, or gene function is ablated by transgenic overex-
pression of antagonists or dominant-negative mutants.
This approach establishes what role the endogenous
protein actually does play in the tissue, with the caveat
that many regulatory systems have built-in redundancy that
may obscure an important role unless multiple members of
a gene family are inactivated simultaneously. For example,
there are three isoforms of TGF-b, all of which are
expressed in the mammary gland, and it is not clear to what
extent they can functionally compensate for each other.
Results from both approaches should be interpreted with
care because of the possibility of confounding systemic or
organismal effects. To be certain that an observed pheno-
type is due to a direct effect on the mammary gland,
ideally all animal models should be subjected to the rigor-
ous test of transplantation of the genetically modified
mammary epithelium onto the cleared fat pad of syngeneic
or immunocompromised hosts. If the original mammary
phenotype is also observed in the transplant, this confirms
that the genetic manipulation affected the mammary gland
directly. This technique also gives useful information about
stromal–epithelial interactions. Only one of the TGF-b-
related models [whey acidic protein (WAP)-TGF-b1] has
been subjected to this type of analysis so far, so results
from the others should be considered provocative but in
need of further confirmation.
Gain-of-function models
Potential for complex regulatory roles in ductal and lobular
development
TGF-b1 has been targeted to the mammary gland using two
different promoters, and the resulting mice showed different
phenotypes [7,8•], probably due to the differing temporal
and spatial patterns of expression of the two promoters. The
WAP promoter is very specific for the mammary epithelium,
but pregnancy and lactation are required for high level
expression of transgene because WAP is a milk protein.
Thus, the virgin gland cannot be readily studied with this
construct. In contrast, the mouse mammary tumor virus
(MMTV)-long terminal repeat (LTR) promoter/enhancer
element drives gene expression in the virgin as well as lac-
tating glands. It is less specific, however, and shows expres-
sion also in other tissues such as the salivary gland, which
can have potentially confounding effects.
WAP-TGF-b1 mice, in which TGF-b was targeted primarily
to the secretory epithelium and its direct progenitors,
showed a lactation-deficient phenotype. Ductal develop-
ment of the mammary glands was not overtly impaired, but
the formation of lobuloalveolar structures and the produc-
Figure 1
Transforming growth factor (TGF)-b has tumor suppressor and
oncogenic activities. Acting directly on the mammary epithelium, TGF-b
could suppress tumorigenesis through a number of mechanisms,
including inhibition of epithelial cell proliferation, induction of apoptosis
or senescence in initiated cells, and maintenance of genomic stability.
All of these activities require an intact epithelial response to TGF-b.
TGF-b can also have pro-oncogenic effects. These may be either
direct, or indirect via the stroma. Direct effects include the promotion
of the epithelial–mesenchymal transition and invasiveness, and an
increase in production of parathyroid hormone-related peptide
(PTHrP). These are also dependent on an intact epithelial response
system. Indirect effects include the induction of angiogenesis, and
suppression of the immune surveillance system. The indirect
oncogenic effects are presumed to dominate when epithelial
responsiveness to TGF-b is lost.Breast Cancer Research    Vol 2 No 2 Wakefield et al
tion of milk were largely suppressed [7]. It was proposed
that TGF-b had two effects: it induced apoptosis of cells
in the developing alveoli; and it directly or indirectly
induced accelerated senescence of the multipotential
mammary stem cell compartment [9•]. In contrast, when
TGF-b1 was overexpressed from the MMTV promoter/
enhancer (MMTV-LTR), the mice showed impaired devel-
opment of the mammary ductal epithelium, but alveolar
outgrowth and lactation occurred normally from the
hypoplastic ductal tree. Interestingly, the nature of the
target cell may determine the mechanism of the TGF-b
response. In the alveolar compartment, TGF-b induced
apoptosis without effects on proliferation, whereas in the
ductal compartment it inhibited proliferation.
Together the data suggest that endogenous TGF-bs could
play an important role in determining the balance of cells
in the ductal versus lobular progenitor compartments, and
the fate of cells within those compartments. We now need
to know in which compartments endogenous TGF-bs are
normally expressed or activated, as this will give insight
into whether they play these roles in the normal mouse.
Since stem cells are the likely targets of carcinogenic
events [10], it is particularly provocative that TGF-bs may
be important in regulating mammary stem-cell kinetics.
For both the WAP-TGF-b1 and MMTV-TGF-b1 mice, the
TGF-b1 construct that was used was a constitutively acti-
vated mutant form. It is noteworthy that no phenotype was
obtained when the native latent form of TGF-b1 was over-
expressed from the MMTV-LTR [8•]. This suggests that
activation rather than production of latent TGF-b is a key
limiting step in controlling TGF-b activity in the normal
mammary gland. Currently, the mechanism for activation of
latent TGF-b in the mammary gland is unknown, and this is
a very important area for further investigation.
Protection against tumorigenesis
What effect does overexpression of TGF-b have on
tumorigenesis? To address this question, tumorigenesis
was initiated in the MMTV-TGF-b1 mice either by treatment
with the mammary carcinogen 7,12-dimethylbenz-[a]-
anthracene or by intercrossing with mice overexpressing
the oncogene TGF-a in the mammary gland [11••]. In both
cases the incidence of mammary tumors was reduced in
MMTV-TGF-b1 mice compared with wild-type controls.
This suggests that local overexpression of TGF-b1 may
suppress mammary tumorigenesis, at least in the early
stages. The observations raise the exciting possibility that
local enhancement of the endogenous TGF-b system,
through the use of pharmacologic agents, could prevent
or delay the development of breast cancer. However,
enthusiasm for this approach should be tempered by
recent findings that a reduction in type II TGF-b receptor
levels may occur very early in the genesis of some human
breast cancers [5••]. When this occurs, locally increased
Table 1
Transgenic mouse models designed to address the roles of TGF-b bs in the mammary gland
Developmental
Model Transgene Expression pattern phenotype Tumor phenotype References
Gain-of-function models
MMTV-TGF-b1
S223/225 Constitutively Mammary epithelium Decreased ductal Inhibition of tumorigenesis [8•,11••]
activated form of development in young induced by chemical
TGF-b1 animals carcinogens or oncogenes
WAP-TGF-b1
S223/225 Constitutively Mammary epithelium, Inability to lactate due to Inhibition of tumorigenesis [7,9•] (Smith G,
activated form of specifically in lobulo- decreased maintenance induced by TGF-b unpublished 
TGF-b1 alveolar progenitors and of lobuloalveolar structures data)
fate-committed daughters
Loss-of-function models
MMTV-DNR Dominant-negative Mammary epithelium Precocious lobuloalveolar Increased spontaneous [27•] (Moses H,
mutant type II development and tumorigenesis in aged mice unpublished 
TGF-b receptor production of milk data)
proteins in virgins
MMTV-DNR Dominant-negative Mammary epithelium Increased lobuloalveolar Increased tumorigenesis [28••]
mutant type II development in virgins in response to carcinogens
TGF-b receptor
MT-DNR Dominant-negative Mammary stroma Increased ductal Not described [29•]
mutant type II branching
TGF-b receptor
DNR, dominant-negative mutant type II transforming growth factor-b receptor; MMTV, mouse mammary tumor virus; WAP, whey acidic protein; MT,
metallothionein promoter; TGF, transforming growth factor.TGF-b could provide a positive selective pressure for out-
growth of initiated TGF-b-resistant clones, and might actu-
ally promote tumorigenesis rather than suppressing it [12].
This is an issue that could be addressed experimentally by
crossing the MMTV-TGF-b1 mice with the MMTV-domi-
nant-negative mutant type II transforming growth factor-b
receptor (DNR) mice, which have diminished epithelial
responsiveness to TGF-b (see below).
Loss-of-function models
Negative regulatory roles in normal mammary gland
development
The TGF-bs signal through a pathway involving activation
of serine–threonine kinase receptors and downstream
signal transduction molecules termed ‘Smads’ [13].
Germline knockouts for TGF-b2 and TGF-b3, the type II
TGF-b receptor, and the signal transduction components
Smad2, and Smad4 are all embryonic or perinatally lethal,
which is consistent with critical roles for TGF-b family
members during development [14–17,18•]. Of the knock-
outs on this pathway that have been generated to date,
the only ones that survive birth are the TGF-b1-null and the
Smad3-null mice [19–22,23•]. In the case of the TGF-b1-
null mice, survival to birth is dependent on the mouse
strain [24]. The TGF-b1-null mice that do survive birth go
on to die of a multifocal inflammatory syndrome soon after
weaning [19,20], but their survival can be further extended
by crossing onto immunodeficient or p21waf1/cip1-null back-
grounds [25] (Letterio JJ, personal communication).
Smad3-null mice have immune and skeletal defects, but
can survive up to approximately 8 months of age
[21,22,23•].
So far there have been no reports on mammary gland
development in the TGF-b1-null mice whose lifespan has
been extended into and beyond puberty through the use
of immunosuppressants or immunodeficient genetic back-
grounds. TGF-b1
+/– mice, however, which have just one
functional TGF-b1 allele, show an accelerated develop-
ment of the mammary ductal tree during puberty, and an
increased proliferation in the mammary epithelium in
response to hormonal stimulation (Barcellos-Hoff M-H,
personal communication). These observations are consis-
tent with a role for endogenous TGF-b1 in limiting prolifer-
ation of the ductal epithelium in response to ovarian
hormones. The presence of a mammary phenotype in the
TGF-b1
+/– mice suggests that there may be pronounced
dosage effects in the TGF-b system. It might therefore be
instructive to examine the mammary glands of the het-
erozygous forms of some of the TGF-b system knockout
models, such as the type II receptor knockout, that are
embryonically lethal in their homozygous form.
TGF-bs are thought to signal primarily through two
pathway-restricted Smad signal transduction proteins,
Smad2 and Smad3, and the common mediator Smad,
Smad 4 [13]. Smad2 and Smad3 are also utilized by the
activins, which are closely related TGF-b family members.
Our preliminary work with the Smad3-null mice indicates
that these mice have underdeveloped mammary glands (Y
Yang, unpublished data) This is opposite to the phenotype
observed with the TGF-b1
+/– mouse (see above), but is
similar to that observed in activin-bB knockout mice, which
show retarded ductal elongation and alveolar morphogen-
esis [26]. Thus, Smad3 may be more important for the
mediation of activin signaling in the virgin mammary gland,
with the TGF-b path utilizing a different pathway-restricted
Smad, possibly Smad2.
To get around the problems of embryonic lethality seen
with germline knockouts, TGF-b function has been specifi-
cally ablated in the mammary gland through targeted over-
expression of a dominant-negative mutant type II
transforming growth factor-b receptor (DNR). Expression
of the DNR from the MMTV-LTR resulted in a phenotype
of precocious lobuloalveolar development and premature
production of milk proteins in the mammary glands of
virgin mice [27•]. Increased lobuloalveolar formation was
also observed in an independently derived MMTV-DNR
model in a different strain of mice [28••]. In contrast, tar-
geting the DNR to the mammary stroma, using a metalloth-
ionein promoter, resulted in increased ductal branching,
associated with increased expression of the morphogen,
hepatocyte growth factor [29•]. Taken together, these
results suggest that endogenous TGF-bs have both direct
and indirect actions on the mammary epithelium. TGF-bs
act directly on the mammary epithelium to prevent func-
tional differentiation in the absence of the appropriate hor-
monal signals, whereas they act indirectly through the
stroma to limit ductal branching and maintain correct
ductal spacing (Fig. 2).
Tumor suppressor activity in the mammary gland
If endogenous TGF-bs are important tumor suppressors in
the mammary gland, one would predict that mice with com-
promised TGF-b function would show increased mammary
tumorigenesis. Interestingly, both Smad3–/– and TGF-b1
–/–
mice show a significant incidence of spontaneous colorec-
tal tumors, but to date no mammary tumors have been
described in either model [23•,30••]. Gastrointestinal tumors
in humans show a much higher incidence of mutations and
deletions in the TGF-b receptors and Smads than do most
other human tumors. Together the data suggest that
TGF-bs may play a uniquely critical role as tumor suppres-
sors in the gastrointestinal tract. Other organs, such as the
breast, may have a more redundant system of defenses, of
which the TGF-b system is just a part.
Clearly, however, endogenous TGF-bs do have tumor sup-
pressor activity in the mammary gland. The evidence in
support of this comes from work with the MMTV-DNR
transgenic mice. The dominant-negative receptor approach
http://breast-cancer-research.com/content/2/2/100is expected to diminish responsiveness to all three TGF-b
isoforms, and to reduce or eliminate downstream signaling
through all Smad transduction components. It should there-
fore overcome issues of functional redundancy within the
TGF-b system. In one model, the carcinogen 7,12-dimethyl-
benz-[a]-anthracene caused a significantly increased inci-
dence of mammary tumors in MMTV-DNR mice compared
with wild-type controls [28••]. In another model, aged multi-
parous MMTV-DNR mice showed an increased incidence
of spontaneous mammary tumorigenesis (Moses H, per-
sonal communication). Tumors in both models arise rela-
tively late, suggesting that multiple cooperating oncogenic
events are required for a tumor to develop. Together, these
data provide evidence that endogenous TGF-bs have tumor
suppressor activity in the mammary gland, and that this role
is compromised by decreasing the TGF-b responsiveness
of the mammary epithelium.
The future: conditional expression systems
and molecular mechanisms
We have only begun to address the complex role that the
TGF-b system may play in mammary tumorigenesis.
Because it is likely that TGF-bs play different roles at dif-
ferent stages of the process, a critical advance will be the
use of transgenic systems that can be regulated or condi-
tional knockout technologies to allow local TGF-b expres-
sion or response to be manipulated in a time-dependent
manner. With these approaches we can determine
whether upregulating TGF-b expression after the
mammary gland is fully developed will still result in tumor
suppression, or whether the suppressive effect is entirely
due to the diminished target size for carcinogenic events
presented by the hypoplastic epithelium. Similarly, upregu-
lating TGF-b expression after a mammary tumor has
become established will allow one to ask whether the
oncogenic rather than suppressor activities of TGF-b dom-
inate during the late stages of tumorigenesis.
The importance of dosage, both of the ligand and the
response system, can also be addressed. One very
intriguing question is the issue of whether the oncogenic
and tumor suppressor activities of TGF-b might occur at
different threshold levels of receptor activation. Reduced
signaling secondary to reduced receptor activation or
expression might modulate the nature of Smad signaling
and the cross-talk with other mitogenic pathways [13]. It
might also qualitatively affect the nature of the genes
induced or repressed by TGF-bs. For example, activin, a
closely related TGF-b family member, has been shown to
induce different genes at different levels of receptor occu-
pancy [31•]. It is interesting that, although TGF-b receptor
expression is decreased in early breast lesions and some
breast cancer cell lines, complete genetic inactivation of
receptors or Smads is very rare [32,33]. Because TGF-b
has some pro-oncogenic activities with an epithelial target
(eg induction of parathyroid hormone-related peptide, and
increased invasion and metastasis [33,35]), it is tempting
to speculate that these activities may occur at lower levels
of receptor activation than are required for growth inhibi-
tion. Thus, a decrease in TGF-b responsiveness to a level
that permits oncogenic activities, but prevents suppressor
activities, might actually be more oncogenic than a total
loss of response.
Another particularly key area for further exploration is the
question of the mechanisms that underlie the suppressor
and oncogenic activities of TGF-bs in vivo. This issue has
not been addressed in any of the mammary models to
date. Candidate mechanisms are shown in Figure 1. It is
interesting that for the colon cancers that arise sponta-
neously in the TGF-b1 knockout mice, there is no evidence
for a change in rates of cell proliferation or apoptosis
[30••]. Rather, it was suggested that TGF-b may normally
play a role in the maintenance of the overall tissue archi-
tecture, and that disruption of this may predispose to
malignancy. Genetically engineered mouse models are
uniquely well suited for analysis of effects on this type of
higher order organizational process.
Conclusion
The data from mouse models suggest that TGF-bs play
roles in regulating both morphogenesis and functional dif-
ferentiation of the mammary gland, with mammary stem
cells or lineage-restricted progenitor cells being important
targets for some of these activities. Experimental over-
expression of TGF-b inhibits tumorigenesis in the
mammary gland, whereas loss of TGF-b responsiveness
promotes it. This suggests that the endogenous TGF-b
system has tumor suppressor activity, and provides a
mechanistic underpinning for the recent observations that
decreased expression of TGF-b receptors in early stage
human breast hyperplasias correlates with increased prob-
ability of subsequently developing invasive breast cancer.
The relatively poor penetrance of the tumorigenic pheno-
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Figure 2
Transforming growth factor (TGF)-b has direct and indirect effects on
morphogenesis and function of the mammary epithelium. TGF-b acts
directly on the epithelium to prevent precocious alveolar development
and milk protein production in virgin mice. Acting indirectly, via the
stroma, it may inhibit ductal branching, possibly through effects on
activity of the morphogen hepatocyte growth factor.types and the late age of tumor onset in the mouse
models, however, suggest that many other events must
cooperate with loss of TGF-b response for a breast tumor
to develop. Alternatively, they may reflect the complex dual
role of TGF-bs as both oncogenes and suppressors. This
will be a fruitful area for further investigation.
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